Discuss the need for new therapies in children with juvenile rheumatoid
arthritis (JRA), including therapies such as celecoxib.
Discuss the safety of celecoxib when used in children with JRA based on
the data derived from the pediatric studies, the known risks, including
cardiovascular risks, in adults and the risks of alternative therapies.